Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPendingWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 7 studies. IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number TBD IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Pending IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number TBD
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Pending
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
